“I think all too often we underestimate the impact of a cancer diagnosis on the mental health and well-being of the individual, thus it goes unaddressed.” ~Stephanie Zimmerman, MSN Receiving a diagnosis of cancer can bring on feelings of worry, fear, dread, anger, uncertainty and loss. Research indicates that, for some people, these symptoms of...
Read More
Video information: After receiving a successful treatment, it’s recommended that patients turn to maintenance therapy to help safeguard their quality of life and help control the residual myeloma cells from developing. The landscape for maintenance therapy continues to expand as the potential effects of new immuno-drugs emerge. Listen in as...
Read More
Video information: In this informative and optimistic edition of “Ask the Expert,” Dr. Gareth Morgan, Professor of Medicine and Director of the UAMS Myeloma Institute, reveals what health prerequisites multiple myeloma patients must reach before they can become cured and what tools are available to help attain that goal. He also poses...
Read More
In a nutshell This paper studied the use of novel drugs with salvage autologous stem cell transplant in relapsed multiple myeloma. This study concluded that salvage autologous stem cell transplant is safe and effective for patients with relapsed multiple myeloma. Some background For patients with newly diagnosed multiple myeloma aged up to...
Read MoreIn a nutshell This paper studied the impact of nerve damage in patients with multiple myeloma. This study concluded that more than half of patients reported experiencing symptoms of nerve damage. Some background Use of drugs such as thalidomide (Thalomid), lenalidomide (Revlimid) and bortezomib (Velcade) have improved outcomes for patients...
Read More
In July 2017, the American Society of Clinical Oncology (ASCO) conducted the National Cancer Opinion Survey to find out what people in the US know about cancer. ASCO released the results in October. The findings have already influenced recommendations made by the organization. Beliefs About Cancer Risk Among other questions, the survey asked 4,016...
Read More
In It’s All In Your Gut, A High Fiber Diet and the Immune System, we introduced the microbiome that lives in our body. It helps with our digestion and makes the short-chained fatty acids (SCFAs) that are important to our immune system. Now several recent studies are looking at bacteria in the bodies of people with cancer. Specifically, these...
Read More
In a nutshell This paper studied the safety and efficacy of marizomib, pomalidomide (Pomalyst) and dexamethasone (Ozurdex) in the treatment of relapsed or refractory multiple myeloma. The authors concluded the treatment was well tolerated and effective. Some background Multiple myeloma is a cancer of the plasma cells (type of...
Read More
In a nutshell This paper studied the use of bone targeting agents in patients with multiple myeloma. The authors concluded that there could be insufficient bone targeted treatment in patients with multiple myeloma. Some background Multiple myeloma is a cancer of the plasma cells (type of white blood cell). This causes bone destruction, high...
Read More
In a nutshell This paper studied the risk factors of progression in smoldering myeloma. Reduced immunoglobulin and high levels of plasma cells were found to increase the risk of progression. Some background Multiple myeloma is a cancer of the plasma cells (type of white blood cell). Smoldering multiple myeloma is a precancerous form of...
Read More
In a nutshell This paper studied the effectiveness of venetoclax (Venclexta) for the treatment of relapsed or refractory multiple myeloma. Venetoclax at a daily dose up to 1200 mg showed promise in treating patients with relapsed or refractory multiple myeloma with the t(11;14) genetic mutation. Some background Multiple myeloma is a cancer...
Read More
In a nutshell This paper studied the effectiveness of bortezomib (Velcade), cyclophosphamide (Cytoxan) and dexamethasone in patients with multiple myeloma who had not been previously treated. The combination of bortezomib, cyclophosphamide and dexamethasone was found to be effective and well-tolerated. Some background Multiple myeloma is a...
Read More
